Literature DB >> 3377893

Mucoepidermoid tumors of salivary glands. A long term follow-up study.

O J Jensen1, T Poulsen, T Schiødt.   

Abstract

Mucoepidermoid tumors of salivary glands are relative rare and it has often been difficult to correlate the pathologic features and clinical aspects. The literature recommends long term follow-up studies. The object of the present study was therefore to follow this recommendation. The clinico-pathological features of 39 mucoepidermoid tumors are presented. The material was retrieved from the files of the pathological institute, Rigshospitalet, Copenhagen, during the period 1941-75. All patients, 24 males, 15 females, were followed for a minimum of 5 years. The lesions were classified into low grade (13 cases), intermediate grade (14 cases) and high grade (12 cases). The corresponding 5, 10 and 15 years cumulative survival rates were 92%, 92%, 92% for low grade, 47.4%, 47.4%, 35.5% for intermediate grade and 0%, 0%, 0% for high grade tumors. Thus we found a close correlation between pathology and clinical course. Furthermore, a 5 year observation period appeared an acceptable approach, because 17 of the 18 patients who succumbed of the disease, did so within 4 years following surgery. We consider all grades of mucoepidermoid tumors to be potential malignant. In our study one patient with a low grade tumor died of the disease.

Entities:  

Mesh:

Year:  1988        PMID: 3377893

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  2 in total

1.  Comparative histogenesis and morphogenesis of mucoepidermoid carcinoma and pleomorphic adenoma. An ultrastructural study.

Authors:  I Dardick; M R Gliniecki; J G Heathcote; A Burford-Mason
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Mucoepidermoid carcinoma of the salivary glands, Clinical data and follow-up of 52 cases.

Authors:  K Plambeck; R E Friedrich; D Hellner; K Donath; R Schmelzle
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.